Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline And University Of Nottingham Establish Research Center

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:46am CEST

Drug maker GlaxoSmithKline PLC (>> GlaxoSmithKline plc) and the University of Nottingham said Thursday that they formalized a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.

MAIN FACTS:

-The Laboratory for Sustainable Chemistry is being supported by a GBP12 million grant from Glaxo.

-Shares at 0829 GMT, down 10 pence, or 0.71%, at 1,403.5 pence valuing the company at GBP71.28 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
10/18 GLAXOSMITHKLINE : GSK receives World Health Organization Prequalification for Sy..
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17 GLAXOSMITHKLINE : 11.7% Potential Upside Indicated by Jefferies International
10/17 AGENUS : GSK announces first approval of Shingrix in Canada
10/13 GLAXOSMITHKLINE : shingles vaccine gets approval in Canada
10/13 GLAXOSMITHKLINE : GSK announces first approval of Shingrix in Canada
10/13 GLAXOSMITHKLINE : GSK first approval of Shingrix in Canada
10/12 THIN FILM ELECTRONICS : Thinfilm and GlaxoSmithKline Bring NFC Technology to Lea..
10/12 GLAXOSMITHKLINE : Chinas C-Bridge hires ex-GlaxoSmithKline executive for U.S. in..
10/12 GLAXOSMITHKLINE : Investigators from GlaxoSmithKline plc Report New Data on Phar..
More news
News from SeekingAlpha
10/18 Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
10/17 Dynavax Reports More Good News
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 SANOFI : Upward Trajectory In 2017
Financials ( GBP)
Sales 2017 30 188 M
EBIT 2017 8 480 M
Net income 2017 4 180 M
Debt 2017 13 917 M
Yield 2017 5,22%
P/E ratio 2017 20,01
P/E ratio 2018 16,05
EV / Sales 2017 2,96x
EV / Sales 2018 2,87x
Capitalization 75 427 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,2  GBP
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-1.82%99 651
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423